Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single‐agent activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Tannir, Nizar M., Papadopoulos, Kyriakos P., Wong, Deborah J., Aljumaily, Raid, Hung, Annie, Afable, Manuel, Kim, Jong Seok, Ferry, David, Drakaki, Alexandra, Bendell, Johanna, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251721/
https://www.ncbi.nlm.nih.gov/pubmed/33709428
http://dx.doi.org/10.1002/ijc.33556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251721/
https://www.ncbi.nlm.nih.gov/pubmed/33709428
http://dx.doi.org/10.1002/ijc.33556

Ejemplares similares